

Managing **PSORIATIC ARTHRITIS** in Specialty Practice:


New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic



WEDNESDAY DECEMBER 16, 2020

FACULTY Daniel Furst, MD

Professor of Rheumatology and Medicine University of California, Los Angeles, CA University of Washington, Seattle, WA University of Florence, Floren<u>ce, Italy</u>



The RELIEF Initiative Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic

FACULTY

Daniel E. Furst, MD

Professor of Rheumatology and Medicine University of California, Los Angeles, CA University of Washington, Seattle, WA University of Florence, Florence, Italy

PROGRAM OVERVIEW

This case-based live virtual activity will cover the treatment and management of patients with psoriatic arthritis.

TARGET AUDIENCE

This activity is intended for rheumatologists and rheumatology advanced practice providers (NPs and PAs) who are involved in the care and treatment of patients with psoriatic arthritis.

Learning Objectives

- Identify the risk of COVID-19-related infections in PsA, along with their impact on therapeutic choice
- Pursue strategies to optimize PsA therapy in the COVID-19 era while minimizing risks and adverse events
- Assess methods for better evaluating and communicating with patients through telemedicine and virtual platforms
- Apply new ways to initiate and manage PsA treatment, monitor PsA disease progression and address adverse events via virtual communication

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 Credit[™]. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with psoriatic arthritis. **CNE Credits:** 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Daniel E. Furst, MD, has received grant/research support from Actelion, Amgen, BMS, Corbus, Galapagos GSK, NIH, Novartis, Pfizer, and Sanofi. He is a consultant with Actelion, Amgen, BMS, Corbus, Galapagos Novartis, and Pfizer.

CME Content Review

The content of this activity was independently peer-reviewed. The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer-reviewed by a nurse reviewer. The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Diana Tommasi, Medical Director of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this live virtual activity. To receive CME/CE credit participants must:

- 1. Read the CME/CNE information and faculty disclosures.
- 2. Participate in the live virtual activity.
- 3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at <u>info@medlearninggroup.com</u>




This activity is provided by Med Learning Group.



This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

Supported by an educational grant from Lilly.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.



AGENDA

Introduction/Background

- Epidemiology and pathophysiology
- COVID-19 background
- COVID-19 and rheumatology: implications for assessment and evaluation
- Disease domains and joint manifestations
- Identification and diagnosis

Medical Management of PsA in the COVI-19 Era

- 2019 ACR guidelines and their application to practice
- Therapeutic considerations in COVID-19
- Conventional agents
- Biologics, small molecules:
 - Inhibitors of TNF, IL-12/23, IL-17A, IL-23, phosphodiesterase 4, T cell costimulation, and janus kinases
- Evolving standards of treatment in the COVID-19 era
- Treating-to-target: establishing goals of therapy

Telemedicine and Patient Considerations in the COVID-19 Pandemic

- Early diagnosis and initiation of treatment for long-term success
- Effect of management decisions on patient QoL
- Lowering disease burden (personal, societal, economic) through effective treatment
- Telemedicine: the changing face of rheumatology consults during the pandemic
- Case Study(s)

Conclusions and Q/A

Posting Questions in Zoom Chat

- If you would like to post a question during the presentation, please submit your inquiry in the chat feature.
- Remember to direct all questions to the "co-host." There is a toggle button above the typing space that allows you to specify the location of your message delivery.

Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic

Daniel E. Furst, MD

Professor of Rheumatology University of California in Los Angeles University of Washington, Seattle, Washington University of Florence, Florence, Italy




Learning Objectives

- Identify the risk of COVID-19-related infections in psoriatic arthritis (PsA), along with their impact on therapeutic choice
- Pursue strategies to optimize PsA therapy in the COVID-19 era while minimizing risks and adverse events
- Assess methods for better evaluating and communicating with patients through telemedicine and virtual platforms
- Apply new ways to initiate and manage PsA treatment, monitor PsA disease progression and address adverse events via virtual communication

COVID-19-associated Hyperinflammation

- Clinical deterioration in COVID-19 often occurs 7-10 days after symptom onset when viral titres decline
 - Pathology likely driven by inflammation rather than direct viral injury
- Elevated inflammatory markers in COVID-19 patients are significantly associated with risk of next-day escalation of respiratory support or death (HR, 2.24)



Manson JJ, et al. Lancet Rheumatol. 2020;2:e594-e602. Yang L, et al. Signal Transduct Target Ther. 2020;5:128.

5

Concerns During the COVID-19 Pandemic

- Patients with PsA are not at increased risk of death, invasive ventilation, ICU admission, or serious complications from COVID-19
 - Impact of PsA therapies on COVID-19 disease severity is unknown
- Risk of poor outcomes from COVID-19 appears to be related primarily to general risk factors such as age and comorbidities

Mortality in an Observational Study of COVID-19 Cases in China (n = 72,314)		
Characteristics	Deaths (%)	
All confirmed cases	2.3	
Critical cases	49.0	
 ≥80 years of age 	14.8	
Cardiovascular disease	10.5	
 70-79 years of age 	8.0	
Diabetes	9.2	
Chronic respiratory disease	8.0	
Hypertension	6.0	
Cancer	7.6	

Mikuls TR, et al. Arthritis Rheumatol. 2020;72:1241-1251. Pablos JL, et al. Ann Rheum Dis. 2020;79:1544-1549. Wu Z, et al. JAMA. 2020;323:1239-1242. Wollina U, et al. Dermatol Ther. 2020;33:e13743.

Impact of PsA Comorbidities on COVID-19 Outcomes

- PsA is associated with a higher incidence of CV disease, metabolic syndrome, obesity, diabetes, dyslipidemia, and IBD
- Older age, male sex, and previous comorbidity increased the risk of severe COVID-19 in patients with rheumatic disease and nonrheumatic disease
 - Diabetes and CV disease were associated with a significantly increased risk of severe COVID-19 in rheumatic patients compared to nonrheumatic patients


	Relative ris	k (95% Cl)		
Variable	Non-rheumatic cohort	Rheumatic cohort	P value	
Age over 60 years	3.70 (1.99 to 6.93)	4.04 (2.30 to 7.08)	0.841	
Male sex	2.16 (1.39 to 3.35)	1.58 (1.09 to 2.29)	0.286	
Obesity	1.22 (0.72 to 2.06)	1.62 (1.10 to 2.36)	0.393	
Diabetes	0.95 (0.53 to 1.70)	1.93 (1.34 to 2.79)	0.038	
Hypertension	1.64 (1.07 to 2.53)	2.27 (1.49 to 3.46)	0.290	
CV disease	1.44 (0.90 to 2.33)	2.92 (2.04 to 4.17)	0.020	
Lung disease	1.57 (1.00 to 2.46)	1.74 (1.19 to 2.55)	0.723	


Pablos JL, et al. Ann Rheum Dis. 2020;79:1544-1549.

7


///////////////////////////////////////	<u> ////////////////////////////////////</u>	<u> </u>
CO	VID-19 Treatment N	lodifications
Treatment of Rheumatic Disease in the Absence of COVID-19 Infection or Exposure		All recommendations based on very low
HCQ/CQ, SSZ, MTX, LEF, immunosuppressants (tacrolimus, CSA, MMF, AZA), biologics, JAK inhibitors, NSAIDs	Continue therapy	quality of evidence and moderate to high consensus
Low-dose corticosteroids	May be started if clinically indicated (<10 mg prednisone equivalent/day)	Recommendations are for rheumatic disease in general and are not subdivided
Following SAR	RS-CoV-2 Exposure	by patient disease. There are no specific
HCQ/CQ, SSZ, NSAIDs	May be continued	recommendations for PsA.
Immunosuppressants (tacrolimus, CSA, MMF, AZA), non-IL-6 biologics, JAK inhibitors	Stop therapy temporarily, pending a negative COVID-19 test or 2 weeks of symptom-free observation	 May reinitiate therapy within 7-14 days of symptom resolution for those with mild COVID-
IL-6 inhibitors	May be continued in select circumstances	19
Documented or p	presumptive COVID-19	
HCQ/CQ	May be continued	 Consider reinitiating therapy in 10-17 days after
SSZ, MTX, LEF, non-IL-6 biologics, immunosuppressants, and JAK inhibitors	Withhold or stop therapy	 positive PCR results if asymptomatic COVID-19 Timing of reinitiating therapy after severe
NSAIDs	Should be stopped in patients with severe respiratory symptoms	COVID-19 should be made on case-by-case basis
AZA = azathioprine; CSA = cyclosporine A; CQ =	= cloroquine; HCQ = hydroxychloroquine; IL = interleu	 ıkin; JAK = Janus kinase; LEF = leflunomide; MMF = mycophenolate


AZA = azathioprine; CSA = cyclosporine A; CQ = cloroquine; HCQ = hydroxychloroquine; IL = interleukin; JAK = Janus kinase; LEF = leflunomide; MMF = mycophenolate mofetil; MTX = methotrexate; NSAID = nonsteroidal anti-inflammatory drug; SSZ = sulfasalazine Mikuls TR, et al. Arthritis Rheumatol. 2020;72:1241-1251.













13



APR = apremilast; CSA = cyclosporine; IL = interleukin; LEF = leflunomide; MTX = methotrexate; NSAID = nonsteroidal anti-inflammatory drug; OSM = oral small molecule; SSZ = sulfasalazine; TNFi = tumor necrosis factor-alpha inhibitor. Singh JA, et al. Arthritis Rheumatol. 2019;71:5-32.



Kingsley GH, et al. Rheumatology (Oxford). 2012;51:1368-1377.

15

CSA in Psoriasis and PsA

- CSA 2.5-5 mg/kg/day yielded PASI75 response in 28% to 97% of patients
- Remission could be maintained at CSA dose of at least 3mg/kg/day
- More than 50% of patients treated with CSA may have an increase in serum creatinine value >30% of baseline if treatment is prolonged for 2 years

24 Week Randomized Open NSAID* Controlled Study of Cyclosporin A in PsA (N=99)

	P-value	Significance CSA vs NSAID*
ACR50	0.02	+
ACR70	0.05	+
Swollen Joint Count	0.05	+
Tender Joint Count	0.01	+
Pain	0.002	+
Patient Global improved ≥1 point	0.04	+
MD Global improved ≥1 point	0.01	+


*NSAID +/- prednisone 5 mg daily +/- analgesics

Salvanarani C, et al. J Rheum. 2001;28:2274-2282. Maza J-H, et al. JEADV. 2011;25(2):19-27.


Adalimumab Or Cyclosporine as Monotherapy or Combination For Severe PsA: A Prospective, 12-month, Observational Study


- A 12-month, observational study of 170 TNFiand cyclosporine-naïve patients
- Patients who received adalimumab (40mg Q2W) (n=57), cyclosporine (2.5-3.75 mg/kg/day) (n=58), or their combination (n=55)
- MTX-IR (25 mg weekly or less, for a minimum of 6 months)
- Assessments: 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 months
- Combination therapy improved PASI50 response rates but NOT beyond the effect of cyclosporine monotherapy (not shown)

MTX-IR = methotrexate inadequate response Karanikolas GN, et al. *J Rheumatol*. 2011;38:2466-2474.



























Betts KA, et al. Arthritis Rheumatol. 2015;67(10): Abstract 2868. Strand V. Rheumatol Ther. 2017;4:349-362.




Missing data were imputed as nonresponse; only response-evaluable patients were included. *P<0.0001; **P=0.0001; †P<0.001; ‡P<0.05 Thaci D, et al. JAAD. 2015;73(3):400-409.

25


Comm	on Adverse	e Events ¹		
	SEC 300 mg	SEC 150 mg	Placebo	Warnings ²
URTI	4 (4%)	8 (8%)	7 (7%)	1. Infection
Nasopharyngitis	6 (6%)	4 (4%)	8 (8%)	2. Tuberculosis
Diarrhea	2 (2%)	2 (2%)	3 (3%)	
Headache	7 (7%)	4 (4%)	4 (4%)	3. Hypersensitivity
Nausea	3 (3%)	4 (4%)	4 (4%)	reactions
Sinusitis	1 (1%)	2 (2%)	1 (1%)	4. New or worsening
Psoriatic arthropathy	0	3 (3%)	2 (2%)	inflammatory
Urinary tract infection	2 (2%)	4 (4%)	4 (4%)	bowel disease
Hematuria	2 (2%)	3 (3%)	1 (1%)	
Vomiting	2 (2%)	2 (2%)	1 (1%)	


URTI = upper respiratory tract infection.

1. McInnes IB, et al. Lancet. 2015;386:1137-1146. 2. Secukinumab (Cosentyx®) PI 2017 (www.pharma.us.novartis.com/sites/www.pharma.us. novartis.com/files/cosentyx.pdf).











- joint and skin disease (ACR50 and PASI 100) in patients with active PsA and inadequate response to csDMARDs
- Ixekizumab was non-inferior to adalimumab for ACR50 response (IXE: 51%, ADA: 47%) but superior for PASI 100 response (IXE: 60%, ADA:47%, P= .001)
 Mease PJ, et al. Ann Rheum Dis. 2020;79:123-131.


		Adverse Eve	
Ixekizuma	b Adverse Even	ts	
	IXE 80 mg (n=1167)	Placebo (n=791)	Warnings 1. Infection
Injection site reactions	196 (17%)	26 (3%)	2. Tuberculosis 3. Hypersensitivity
Upper respiratory tract infections	163 (14%)	101 (13%)	reactions 4. Inflammatory bowel
Nausea	23 (2%)	5 (1%)	disease
Tinea infections	17 (2%)	1 (<1%)	







McInnes IB et al. Lancet. 2013;382:780-789. Ritchlin C et al. Ann Rheum Dis. 2014;73:990-999.




33

Ustekinumab Adverse Events

- Meta-analysis of 9626 patients in 30 RCT of 16 weeks duration
- AEs and SAEs include infections, cough, headache, upper respiratory tract infection, nausea, injection site reactions, CV event, cancer, and death


Adverse events	UST	Placebo	P value
Infections	1210 (19.7%)	588 (17.1%)	<0.01
Nasopharyngitis	318 (5.2%)	162 (4.7%)	0.31
Cough	21 (2.3%)	25 (4.8%)	0.01
Upper respiratory tract infection	150 (3.2%)	201 (7.1%)	<0.001
Nausea	113 (4.8%)	58 (5.0%)	0.80
Headache	302 (6.1%)	141 (5.1%)	0.06
Infusion/Injection site reaction	149 (3.9%)	44 (2.0%)	<0.001
Malignancy	3 (0.1%)	5 (0.2%)	0.16
Death	5 (0.1%)	1 (0.1%)	0.43
CV	7 (0.2%)	4 (0.2%)	1.00

Rolston VS, et al. Dig Dis Sci. 2020. doi:10.1007/s10620-020-06344-w.




guselkumab Q4W (59%) and Q8W (52%) groups than in the placebo group (22%)


Deodhar A, et al. Lancet. 2020;395:1115-1125.





		G	US
	PBO	100 mg Q8W	100 mg Q4W
Patients with ≥1 AE (%)	60%	54%	55%
SAE (%)	4%	3%	0%
Discontinuation due to AE (%)	2%	2%	1%
Infections (%)	25%	26%	24%
Alanine aminotransferase increase	2%	6%	4%
Aspartate aminotransferase increase	2%	7%	2%
Nasopharyngitis	6%	13%	5%
Upper respiratory tract infection	6%	6%	9%


Deodhar A, et al. Lancet. 2020;395:1115-1125.
























Adverse Events	Placebo (N = 159)	APR 30 BID (24 weeks) (N = 162)	APR 30 BID (5 weeks) (N = 234)
Diarrhea	8 (5.0)	24 (14.8)	32 (13.7)
Nausea	3 (1.9)	26 (16.0)	32 (13.7)
Headache	7 (4.4)	19 (11.7)	23 (9.8)
URTI	6 (3.8)	11 (6.8)	22 (9.4)
Nasopharyngitis	6 (3.8)	8 (4.9)	10 (4.3)
Hypertension	7 (4.4)	5 (3.1)	13 (5.6)
Laboratory values			
ALT >150 u/L	1/158 (0.6)	2/160 (1.3)	3/230 (1.3)
Creatinine elevation	0/158 (0.0)	1/160 (0.6)	2/230 (0.9)
1. Depressio	Warnings on and suicidal be		


APR = apremilast; ALT = alanine aminotransferase.

1. Cutolo M, et al. J Rheumatol. 2016;43:1724-1734. 2. Apremilast (Otezla *) PI (http://media.celgene.com/content/uploads/otezla-pi.pdf).





















	COVID-19 Exposure		
The patient reports	Treatment of Rheumatic Disease Durin	<u> </u>	
that his wife tested positive for COVID-19	Treatment of Rheumatic Disease in the Absenc HCQ/CQ, SSZ, MTX, LEF, immunosuppressants (tacrolimus, CSA, MMF, AZA), biologics, JAK inhibitors, NSAIDs	Continue therapy	
yesterday	Low-dose corticosteroids	May be started if clinically indicated (<10 mg prednisone equivalent/day)	
	Following SARS-CoV-2 Exposure		
 How would you manage this patient's 	HCQ/CQ, SSZ, NSAIDs Immunosuppressants (tacrolimus, CSA, MMF, AZA), non-IL-6 biologics, JAK inhibitors	May be continued Stop therapy temporarily, pending a negative COVID-19 test or 2 weeks of symptom-free observation	
PsA given his exposure	IL-6 inhibitors	May be continued in select circumstances	
to SARS-CoV-2?	Documented or presump	tive COVID-19	
	HCQ/CQ	May be continued	
	SSZ, MTX, LEF, immunosuppressants, non-IL-6 biologics, and JAK inhibitors	Withhold or stop therapy	
	NSAIDs	Should be stopped in patients with severe respiratory symptoms	









COVID-19	Exposure
----------	----------

- The patient receives ixekizumab to manage her condition
- 2 months later, the patient experiences dyspnea, loss of smell, and a cough. She tests positive for COVID-19
- How would you manage this patient's PsA given her COVID-19 diagnosis?

Mikuls TR, et al. Arthritis Rheumatol. 2020;72:e1-e12.

Treatment of Rheumatic Disease During the COVID-19 Pandemic ⁸				
Treatment of Rheumatic Disease in the Absence of COVID-19 Infection or Exposure				
HCQ/CQ, SSZ, MTX, LEF, immunosuppressants (tacrolimus, CSA, MMF, AZA), biologics, JAK inhibitors, NSAIDs	Continue therapy			
Low-dose corticosteroids	May be started if clinically indicated (<10 mg prednisone equivalent/day)			
Following SARS-CoV-2 Exposure				
HCQ/CQ, SSZ, NSAIDs	May be continued			
Immunosuppressants (tacrolimus, CSA, MMF, AZA), non-IL-6 biologics, JAK inhibitors	Stop therapy temporarily, pending a negative COVID-19 test or 2 weeks of symptom-free observation			
IL-6 inhibitors	May be continued in select circumstances			
Documented or presumptive COVID-19				
HCQ/CQ	May be continued			
SSZ, MTX, LEF, immunosuppressants, non-IL-6 biologics, and JAK inhibitors	Withhold or stop therapy			
NSAIDs	Should be stopped in patients with severe respiratory symptoms			

